{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:26:50Z","timestamp":1790526410785,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1\/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was reported, and venetoclax at 400 mg per day was chosen for extension. Eighteen (75%) relapsed and 8 (53%) untreated patients experienced grade 3\/4 adverse events. The complete response rate assessed by positron emission tomography at the end of cycle 6 was 67% in relapsed and 86.6% in untreated patients. MRD clearance for evaluable patients was seen in 71.5% of relapsed (10\/14 patients) and 100% of untreated MRD-evaluable patients (n = 12) at the end of 3 cycles. The median follow-up for relapsed patients was 17 months (range, 10-35 months). The 2-year progression-free survival (PFS) was 69.5% (95% confidence interval [CI], 52.9%-91.4%) and 68.6% (95% CI, 49.5%-95.1%) for overall survival. The median follow-up was 14 months (range, 5-19) for untreated patients, the 1-year PFS was 93.3% (95% CI, 81.5%-100%). The combination of obinutuzumab, ibrutinib, and venetoclax is well tolerated and provides high response rates, including at the molecular level, in relapsed and untreated MCL patients. This trial was registered at www.clinicaltrials.gov as #NCT02558816.<\/jats:p>","DOI":"10.1182\/blood.2020008727","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T18:01:05Z","timestamp":1605204065000},"page":"877-887","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-2128","authenticated-orcid":false,"given":"Steven","family":"Le Gouill","sequence":"first","affiliation":[{"name":"Service d\u2019h\u00e9matologie clinique du Centre Hospitalier Universitaire (CHU) de Nantes, INSERM Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers (CRCINA) Nantes-Angers, Nantes Excellence Trajectory (NeXT) Universit\u00e9 de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"CHU Lille, Universit\u00e9 de Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-752X","authenticated-orcid":false,"given":"David","family":"Chiron","sequence":"additional","affiliation":[{"name":"INSERM, CNRS, Universit\u00e9 de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"CHU Montpellier, Institut de G\u00e9n\u00e9tique Mol\u00e9culaire de Montpellier, INSERM, Universit\u00e9 de Montpellier, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"CHU Dijon, INSERM, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine nucl\u00e9aire CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Universit\u00e9 de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylviane","family":"Ragot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bourgogne Facult\u00e9 de M\u00e9decine, INSERM, CHU Dijon, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bossard","sequence":"additional","affiliation":[{"name":"Service d\u2019anatomopathologie, CHU de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Nadal","sequence":"additional","affiliation":[{"name":"CHU Dijon, INSERM, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"CHU Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9matologie clinique du Centre Hospitalier Universitaire (CHU) de Nantes, INSERM Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers (CRCINA) Nantes-Angers, Nantes Excellence Trajectory (NeXT) Universit\u00e9 de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tchernonog","sequence":"additional","affiliation":[{"name":"CHU Montpellier, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Rossi","sequence":"additional","affiliation":[{"name":"CHU Dijon, INSERM, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-7174","authenticated-orcid":false,"given":"Rory","family":"McCulloch","sequence":"additional","affiliation":[{"name":"Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9matologie clinique du CHU de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Callanan","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bourgogne Facult\u00e9 de M\u00e9decine, INSERM, CHU Dijon, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-6351","authenticated-orcid":false,"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2022041419423992600_B1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022041419423992600_B2","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"2022041419423992600_B3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"2022041419423992600_B4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2022041419423992600_B5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2022041419423992600_B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"2022041419423992600_B7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"2022041419423992600_B8","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"491","key":"2022041419423992600_B9","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"2022041419423992600_B10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022041419423992600_B11","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"key":"2022041419423992600_B12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3389\/fonc.2018.00645","article-title":"BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker","volume":"8","author":"Tessoulin","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"2022041419423992600_B13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"issue":"13","key":"2022041419423992600_B14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"2022041419423992600_B15","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2022041419423992600_B16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2022041419423992600_B17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2022041419423992600_B18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2022041419423992600_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2022041419423992600_B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"issue":"1","key":"2022041419423992600_B21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1191\/1740774506cn134oa","article-title":"The continual reassessment method for dose-finding studies: a tutorial","volume":"3","author":"Garrett-Mayer","year":"2006","journal-title":"Clin Trials"},{"key":"2022041419423992600_B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v054.i13","article-title":"bcrm: Bayesian continual reassessment method designs for phase I dose-finding trials","volume":"54","author":"Sweeting","year":"2013","journal-title":"J Stat Softw"},{"issue":"14","key":"2022041419423992600_B23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2022041419423992600_B24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2022041419423992600_B25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/137\/7\/877\/1888227\/bloodbld2020008727.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/137\/7\/877\/1888227\/bloodbld2020008727.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T15:43:00Z","timestamp":1649950980000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/7\/877\/474141\/Ibrutinib-obinutuzumab-and-venetoclax-in-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008727","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}